å°æ¥éçºãããããããmRNAã¯ã¯ãã³ãææ¯ãšãªãçç±
ããŒã¯ãã«ããæè¿ã®ç ç©¶ãmRNAã¯ã¯ãã³ã®å ç«ã¯è现èã®æšçè§£é€ã«ãã£ãŠåŒ·åãããâŠãã®çã®æå³ã«ã€ããŠïŒ2026幎ïŒ
Michael Palmer, MD
Jul 11, 2026
èªè ã®å€ãã¯ãéºäŒåããŒã¹ã®COVIDã¯ã¯ãã³ããå€ãã®æ¥çš®è ã«æ·±å»ã§ãã°ãã°äžå¯éçãªå¥åº·è¢«å®³ãåŒãèµ·ãããŠããããšããåç¥ã§ãããããŸãããããã®ã¯ã¯ãã³ã®äžã§æãåºã䜿çšãããŠãããã®ãããªãã¡ãã¡ã€ã¶ãŒ/ããªã³ããã¯ç€Ÿè£œãšã¢ãã«ã瀟補ã®ã¯ã¯ãã³ã«ã¯ãæ¹å€ã¡ãã»ã³ãžã£ãŒRNAïŒç¥ããŠmRNAïŒãå«ãŸããŠããããšããåç¥ã§ãããã芳å¯ãããå¥åº·è¢«å®³ã®åå ãšããŠèããããèŠå ã¯ããã€ããããŸãã
mRNAã¯ã¯ãã³ãäœå ã®çްèå ã§åæãèªå°ããã¹ãã€ã¯ã¿ã³ãã¯è³ªã®çŽæ¥çãªæ¯æ§äœçšã
ã¯ã¯ãã³ã«å«ãŸããè質ããç²åã«å«ãŸããéœã€ãªã³æ§è質ã®ååŠçæ¯æ§ã
ãã¡ã€ã¶ãŒ/ããªã³ããã¯ç€Ÿè£œããã³ã¢ãã«ã瀟補ã®äž¡æ¹ã®è£œå€ããã现èDNAãã¯ã¯ãã³è£œé ç±æ¥ã®ãã®ä»ã®æ®çç©ãªã©ã®æ±æç©è³ªãæ€åºãããŠããã1
ã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ãçµå±ã®ãšããç°ç©æåã§ãããããããã«å¯Ÿããå ç«åå¿ãèµ·ãããŸããããã«ããæäœã圢æãããŸãããåæã«ãã®æåãç£çãã现èèªäœãç Žå£ãããŠããŸããŸãã
çåã«æã人ãããã ããããããã®èŠå ã¯ãã¹ãŠçããéèŠãªã®ãããããšã決å®çãªã®ã¯ãã®ãã¡ã®1ã€ã2ã€ã ããªã®ãïŒãã®çåã¯åãªãåŠè¡çãªãã®ã§ã¯ãªããäŸãã°ã€ã³ãã«ãšã³ã¶ãªã©ãCOVID-19以å€ã®çŸæ£ã«å¯ŸããmRNAã¯ã¯ãã³ã®éçºãé²ããããŠããçŸç¶ãèžãŸãããšãå°æ¥éçºãããã¯ã¯ãã³ã«ãããŠãæå®³äºè±¡ã®æ±ºå®çãªåå ãåãé€ãããšã§ãå®å šæ§ãé«ããããšãã§ããã®ã ãããïŒ
ä»®ã«ããããŸã§ä»®èª¬ãšããŠãè°è«ã®ããã«ã次ã®ãããªç¹æ§ãæã€ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãéçºããŠãããèª å®ãªè£œè¬äŒç€ŸãèŠã€ãã£ããšããŸãããã
ã¯ã¯ãã³æåïŒãŠã€ã«ã¹ã®ã¿ã³ãã¯è³ªãã€ã³ãã«ãšã³ã¶ã®å Žåã¯ãããã2çš®é¡ãããã°ã«ããã³ãšãã€ã©ããããŒãŒïŒã¯ç¡æ¯ã§ãããããŸãã¯ç¡æ¯ããŒãžã§ã³ãæåã«éçºãããŠããããã®é åãã¯ã¯ãã³mRNAã«çµã¿èŸŒãŸããã
é©åã«ç²Ÿè£œãããéœã€ãªã³æ§è質ã䜿çšãããã¯ã¯ãã³ã«äœ¿çšããããã®ãããªèè³ªã®æäžéãç¡å®³ã§ããããšã蚌æããããã«ããŸãåç©å®éšã次ã«ããã®ãã©ã³ãã£ã¢ã察象ãšããç¶¿å¯ãªç ç©¶ã宿œãããã
mRNAã¯ãèŠå¶åœå±ã®æ¿èªãåŸãããã ãã§ãªãã忥çç£ããããã¹ãŠã®ãããã«ãããŠãè質ããç²åã«å°å ¥ãããåã«ãDNAããã®ä»ã®è£œé éçšã§çããæ®çç©ããæ éã«åé¢ãããã
ïŒããã¯çŽ æŽããã話ã«èããããããããªãããããã§ã¯ãªããåã«æããããããããã®ã§ãæ°å¹ŽåãŸã§ã¯ãã®ãããªé æ ®ãåœããåã ã£ãã®ã ãïŒ
ãã®ãããªã¯ã¯ãã³ã§ããã°ãäžèšã«æããæœåšçãªæå®³èŠå ã®ãã¡æåã®3ã€ã¯æé€ãããæ®ãã®ã¯4ã€ç®ã ããšãªãããããã£ãŠãéèŠãªåé¡ã¯ãmRNAã¯ã¯ãã³ã«é¢é£ããæå®³äºè±¡ã«ãããŠãæåã«å¯Ÿããå ç«å¿çãã©ã®ãããªåœ¹å²ãæãããããšããç¹ã§ããããã®å ç«å¿çã¯ãããããã¯ã¯ãã³æ¥çš®ã®ãŸãã«ç®çã§ããããããã£ãŠäžå¯æ¬ ã§ãããããã«ãããå ç«å¿çèªäœãmRNAã¯ã¯ãã³ã®æå®³äœçšã®åå ã§ãããªãã°ããã®æè¡ã®å®å šãªäœ¿çšã¯æ ¹æ¬çã«äžå¯èœãšãªãã
å®éããŸãã«ãã®å¯èœæ§ããããã¹ãã£ãªããã»ãã¯ãã£ã圌ã®åŠ»ã«ãªãŒãã»ã©ã€ã¹ããããŠä»ã®æ°åã®ç§åŠè ããã¯ã¯ãã³æ¥çš®ãå§ãŸãåãããããã®ã¯ã¯ãã³ã«ã€ããŠæ©æèŠåãçºãããã£ãããšãªã£ãã®ã§ããæ®å¿µãªããããããã®èŠåã¯ããŸãã«ãæ£åœãªãã®ã§ãããç§ãã¡ã®èæžãmRNAã¯ã¯ãã³ã®æ¯æ§ã ²ã§ã¯ãã¯ã¯ãã³ã«ããæå·ã«é¢ããçµ±èšçããã³çµç¹ç çåŠçç 究³ã®å šäœåããå ç«å¿çãæ±ºå®çãªåœ¹å²ãæãããŠããããšã瀺ããŠãããšèª¬æããŸããã
ãããŠä»ããã®çµè«ãè£ä»ããçŽæ¥çãªå®éšç蚌æ ãåŸãããŸããããã®èšŒæ ã¯ãMarks ãã«ããæè¿çºè¡šãããããŠã¹ç ç©¶ããåŸããããã®ã§ããâŽãã®ç ç©¶ã®å®éã®ç®çã¯ãmRNA ã¯ã¯ãã³ã«å¯Ÿããå ç«å¿çãžã®ããŸããŸãªèåšãçµç¹ã®å¯äžã調æ»ããããšã§ããããã®ãããç ç©¶è ãã¡ã¯å·§åŠãªããªãã¯ãçšããŸãããå®éšã§äœ¿çšããã mRNA ã¯ããã®çºçŸãã€ãŸããããã³ãŒãããæåã®ç£çããåã ã®çµç¹ãèåšã§ç¹ç°çã«é»å®³ãããïŒãã ãå®å šã«æå¶ãããããã§ã¯ãªãïŒããã«èšèšãããŸãããæ¯èŒã®ããã«ãçŸåšèª¿æ»äžã®èåšãå«ããã¹ãŠã®èåšã§å®å šã«çºçŸãã mRNA ãåã±ãŒã¹ã§äœ¿çšãããŸããã3çªç®ã®ããŠã¹çŸ€ã«ã¯ãmRNA ãå«ãŸãªãè質ããç²å (LNP) ã®ã¿ãå«ããåœãã¯ã¯ãã³ã泚å°ãããŸããããããã®LNPã«ã¯ãModerna COVID ã¯ã¯ãã³ã«ãå«ãŸããŠãã SM-102 ãšåŒã°ããã«ããªã³æ§è質ããŸã£ããåãã§ããããšã«æ³šæããŠãã ããã
èèã«é¢ããå®éšã§ã¯ãèçïŒäžéšã®ãŠã€ã«ã¹ææçãCOVIDã¯ã¯ãã³æ¥çš®åŸã«ãèŠãããèèã®ççïŒã¯ãå®éã«æåãç£çãããå Žåã«ã®ã¿çºçããããšãæããã«ãªã£ããããã¯ãMarksãã®è«æããåŒçšããå³1ã«ç€ºãããŠããã

å³1 ïŒæåçºçŸå®éšmRNAãæ³šå°ããŠãã5æ¥åŸã®ããŠã¹èèãžã®CD8 + Tãªã³ãçã®æµžæœ€ãRNA.WTã¯èèã§å®å šã«çºçŸããããã«èšèšãããŠããããRNA.122Tã§ã¯çºçŸãRNA.WTã®çŽ10%ã«æžå°ããŠãããå·ŠïŒä»£è¡šçãªçµç¹åçãå³ïŒçµç¹åç1å¹³æ¹ããªã¡ãŒãã«ãããã®CD8 + TçŽ°èæ°ã3çªç®ã®ãµã³ãã«ïŒãCtrlããšã©ãã«ä»ãïŒã«ã¯ã空ã®ãè質ããç²åãå«ãŸããŠããããmRNAã¯å šãå«ãŸããŠããªããMarksãã®ç ç©¶ã®å³5ããåŒçšã
å³ã¯ãèèãžã®CD8 + Tãªã³ãçã®æµžæœ€ã瀺ããŠããããã®äžã«ã¯ããããTãã©ãŒçްèãé¡èã«å«ãŸããŠããŸããããã¯èçã®ç¹åŸŽã§ããããŠã€ã«ã¹æ§ãèªå·±å ç«æ§ãCOVIDã¯ã¯ãã³æ¥çš®åŸã®èçã®ãããã®å€ç°åã«ãããŠãåæ§ã«èгå¯ãããŸããå¥ã®å®éšã§ã¯ãT现èã®æµžæœ€ãã«ã¹ããŒãŒæŽ»æ§åãããªãã¡ã¢ãããŒã·ã¹ïŒããã°ã©ã çŽ°èæ»ïŒãšäºæ³éãã®çžé¢é¢ä¿ã瀺ãããšã瀺ãããŸããã以äžã®ç¹ã芳å¯ã§ããŸãã
å®éšåç©ã®3ã€ã®ã°ã«ãŒããã¹ãŠã«ãåãéã®è質ããç²åãæäžããããè質ããç²ååç¬ã§ã¯ããªã³ãçã®æµžæœ€ã¯ã»ãšãã©èŠãããªãã£ãã
TçŽ°èæµžæœ€ã¯ãå®å šã«çºçŸããmRNAãæäžãããçŸ€ã§æãé«ãã£ããçºçŸãæå¶ãããmRNAã¯ã¯ãã³ã§ã¯æããã«äœãã£ãããäºæ³ã»ã©å€§ããªå·®ã§ã¯ãªãã£ããmRNAã®æäžéãããªãå€ãã£ããããå ç«å¿çã®å·®ãå°ãããªã£ãå¯èœæ§ãããããšã«çæããå¿ èŠãããïŒå®å šãªçºçŸã«ãã£ãŠå¿çã飜åç¶æ ã«è¿ã¥ãå¯èœæ§ãããããïŒã
å®éšçšmRNAã¯ã¯ãã³ãæäžããã2ã€ã®å®éšåç©çŸ€ã¯ãæ®çDNAãªã©ã®æœåšçãªæ±æç©è³ªãåéæäžãããããšã«ãªããããã«ã䞡矀ã«ãããŠè现èãåã蟌ãã mRNAéãåéã§ãã£ããå¯äžã®éãã¯æåç£çéã§ãã£ãããããã£ãŠãä»åã®çµæã¯ã芳å¯ããããªã³ãçæµžæœ€ã«ãããŠåœè©²æåãæ¯é çãªåœ¹å²ãæãããŠããããšãæç¢ºã«ç€ºããŠããããDNAããã®ä»ã®æ±æç©è³ªã®å¯äžãå®å šã«æé€ããããšã¯ã§ããªãã
ãããã®å®éšã§ã¯ãæåãšããŠç·è²èå ã¿ã³ãã¯è³ªïŒGFPïŒãçšããããã®ã¿ã³ãã¯è³ªã¯å®è³ªçã«ç¡æ¯ã§ããããã§ã«å€ãã®çç©ã«å°å ¥ãããŠããããç®ç«ã£ã害ã¯åãŒããŠããªããå³2ã«ç€ºãããã«ãèçºçãé»å®³ããããšãªãçæ®çŽ°èç³»åã«å°å ¥ããããšãå¯èœã§ããã

å³2 ïŒç·è²èå ã¿ã³ãã¯è³ªïŒGFPïŒãå°å ¥ãçºçŸããã系統ã®ããŠã¹2å¹ãšãéçåããŠã¹1å¹ãç»åã¯Wikimedia Commonsããã
a)ã®è«ç¹ã¯ãè質ããç²åãå®éšçèçã«ãããŠéèŠãªå æé¢ä¿ãæã€ãšããèãã«æããã«åè«ãããã®ã§ãããççã¯mRNAã®åã蟌ã¿ã«ãã£ãŠå·Šå³ãããããã®ç¹ã«ãããŠãã¢ã¹ãã©ãŒãã«ç€Ÿããžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ç€Ÿã補é ããã¢ãããŠã€ã«ã¹ã¯ã¯ãã³ïŒæ¯ç©ïŒã®å¯äœçšã¯ãè質ããç²åãäžåå«ãŸãªãã«ãããããããmRNAã¯ã¯ãã³ã®å¯äœçšãšéåžžã«ãã䌌ãŠããããšã¯æ³šç®ã«å€ãããç·åçãªèšŒæ ã¯ãè質ããç²åãã¯ã¯ãã³ã«ããæå·ã®äž»èŠå ã§ãããšãã䞻匵ãè£ä»ãããã®ã§ã¯ãªãã
b)ã¯ãççã®åŒ·åºŠãæåã®çºçŸã¬ãã«ã«äŸåããããšã瀺ããŠããŸããmRNAã®çºçŸã匱ãå Žåã§ããªã³ãçã®æµžæœ€ãèªããããããšãããDNAæ±æç©è³ªãªã©ã®åœ±é¿ãå®å šã«æé€ããããšã¯ã§ããŸããããã ãããããã®å®éšçšmRNAã¯ã¯ãã³ã¯ç 究宀ã§å°èŠæš¡ã«ãããã»ã¹1ãã«åŸã£ãŠè£œé ããããããåžè²©ã®COVID mRNAã¯ã¯ãã³ãããæ±æåºŠãäœãå¯èœæ§ãé«ãããšã«æ³šæããŠãã ããã
ããããã¹ãŠã¯ãæåã®çºçŸããªã³ãçæµžæœ€ãšççã®äž»èŠå ã§ããããšã瀺åããŠããããããŠããããã®å®éšã§äœ¿çšãããæåã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªãšã¯ç°ãªãç¡æ¯ã§ãããããççã¯ãã®æåã«å¯Ÿããå ç«å¿çã«èµ·å ãããšèããããããŸãã«ãã®ã¡ã«ããºã ããããæ¬ç ç©¶ããã³çŸå®äžçã«ãããäžå¹žãªã¯ã¯ãã³æ¥çš®è ã®ç ççµç¹åŠçæèŠã«æãããåèŽãããããã«ããã®ã¡ã«ããºã ã¯èèã«éãããååãšããŠå šèº«ã®ããããèåšã«åœ±é¿ãäžããã
çµè«ã¯æçœã ã
å®å šãªmRNAã¯ã¯ãã³ã¯ãæ ¹æ¬çã«äžå¯èœã§ããããªããªãã害ãåãŒãäžå¿çãªã¡ã«ããºã ããæãŸããäœçšã¡ã«ããºã ãšåäžã ããã§ããã
ãã®åéã«ç²Ÿéããç§åŠè ãã¡ã¯ãåœåãããã®ããšãçè§£ããŠããŸãããã¯ã¯ãã³æ¥çš®ãå§ãŸããšãã¯ã¯ãã³é¢é£ã®æå®³äºè±¡ãããã«èгå¯ããããããè£ä»ããããŸããããããŠä»ãçŽæ¥çãªå®éšç蚌æ ãåŸãããŠããŸããæ¿æ²»å®¶ãšãã®æå ã§ããç§åŠçã®é£äžãããããç®ãéãã«ã¯ãäžäœäœãèµ·ãããªããã°ãªããªãã®ã§ããããïŒ
ãŸãããã®è°è«ã«ãããŠãCOVID mRNAã¯ã¯ãã³ã«æ€åºãããæ®çDNAããã®ä»ã®æ±ææ žé žãããããå¥åº·ãªã¹ã¯ã軜èŠããæå³ã¯å šããªãããšãä»ãå ããŠãããŸãããããã¯ãç§ãã¡ã®äœçްèã«éºäŒåæå·ãäžãããšããããããªãå±éºããããããŸãããŸããModerna瀟ãšPfizer/BioNTech瀟ããäºåã®å®å šæ§è©ŠéšãåããŠããªãã«ããªã³æ§è質ã䜿çšããããšã容èªããã€ããããããŸãããããããããã§è°è«ããç ç©¶çµæã¯ãããšããããã®åé¿å¯èœãªãªã¹ã¯ãå®å šã«æé€ã§ãããšããŠããã€ãŸããäžè¿°ã®ãããªå®å šã«çŽç²ãªä»®æ³çãªmRNAã¯ã¯ãã³ãéçºãããšããŠããé床ã®èªå·±å ç«çŸæ£æ§ã®ççã®ãªã¹ã¯ã¯äŸç¶ãšããŠæ®ãããšã瀺ããŠããŸãããã®ãªã¹ã¯ã ãã§ããmRNAã¯ã¯ãã³ãšããæŠå¿µå šäœããã£ã±ããšåŠå®ããã«ååãªã»ã©æ·±å»ã§ãã
åç §ïŒMcKernan, K. (2023) Pfizerããã³Modernaã®äºäŸ¡ã¯ã¯ãã³ã«ã¯20ïœ35%ã®çºçŸãã¯ã¿ãŒãå«ãŸããŠãããå€§è žèã§åœ¢è³ªè»¢æèœãæããã
Palmer, M. et al. (2023) mRNAã¯ã¯ãã³ã®æ¯æ§ïŒPDFã¯äžèšã®URLããç¡æã§å ¥æå¯èœïŒã
çµç¹ç çåŠãšã¯ãç å€çµç¹ãèåšãé¡åŸ®é¡ã§èгå¯ããåŠåã§ããã
Marks, A. et al. (2026)ãmRNAã¯ã¯ãã³ã®å ç«ã¯è现èã®æšçè§£é€ã«ãã£ãŠå¢åŒ·ãããæš¹ç¶çްèã®çºçŸã«äŸåããªãããNature Biotechnology ã
